Cypher Drug–Coated Heart Stent
Cordis, a division of Johnson & Johnson, introduced a drug-coated heart stent in 2003 with much fanfare. The stent was believed to be an improvement over previous cardiac stent designs, and, it was hoped, would decrease the significant risk of reclogging of arteries following angioplasty. Unfortunately, a number of patients have experienced reclogging of their arteries and other cardiovascular adverse effects. In addition, a number of patients have developed a hypersensitivity reaction to the anti-rejection drugs that are used to coat the stent and have sustained serious injuries or died as a result.
If you or a loved one are experiencing any of these symptoms or are having serious health problems as a result of a drug-coated heart stent, please contact Alley, Clark & Greiwe to learn more about your legal rights.